This refresh
Data-driven refresh July 13, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow). Scanned every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (5,239 tickers); 1,778 scored on the quality-growth model (financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top Picks — quality compounders at a fair price
1. DOCS — Doximity, Inc. · score 90.1
Health Information Services · price $22.29 · 1Y $24.53 · 5Y $35.91 · 10Y $53.27
FCF $326m C · Rev +13.1% B+ · D/E 0.01 A · P/E 22.7x B+ · PEG 0.59 A-
Why now. The bull case hinges on Doximity’s AI‑driven workflow tool Ask, which embeds evidence‑based data directly into clinicians’ daily routines, locking in the platform’s relevance and expanding high‑margin sponsored content revenue. The business is scaling at 13.1% YoY revenue growth, converting that into a 30.4% profit margin and generating $326 m of free cash flow on a $4.1 b market cap, delivering an ~8% FCF yield. With a PEG of 0.59, the growth is cheap relative to earnings, meaning the compounding engine of AI‑enhanced engagement and premium ad pricing can persist for years.
Moat. Doximity’s moat derives from its entrenched physician network—over a million U.S. clinicians rely on its newsfeed, AI assistant Ask and Scribe tools, creating a high switching cost because clinical workflows are built around the platform’s HIPAA‑compliant data. This network fuels pricing power for sponsored content, reflected in a 20.6% ROE, and cannot be replicated quickly by generic ad platforms lacking deep clinical integration.
Risk. The bear case points to a valuation premium: a forward P/E of 22.7 for a growth name may be stretched if revenue growth decelerates from the current 13.1% pace, especially as larger ad‑tech rivals target the same physician audience. A beta of 1.29 amplifies market volatility, and any slowdown in ad spend or AI adoption would compress the 30.4% margin. A breach of the 13% growth threshold would trigger a sell‑off, confirming the downside thesis.
Horizon. 1-3 yr $24.53 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $35.91 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $53.27 if current growth sustains into durable earnings power.
2. ADBE — Adobe Inc. · score 89.6
Software - Application · price $230.61 · 1Y $272.48 · 5Y $398.93 · 10Y $591.79
FCF $10.3b A- · Rev +11.5% B · D/E 0.61 C+ · P/E 13.2x A- · PEG 0.61 A-
Why now. Adobe's dominant position in creative and experience management software, particularly within its Digital Media and Digital Experience segments, offers a compelling growth story at an attractive valuation. The company's ability to generate $10.3B in TTM free cash flow and maintain a robust 28.7% profit margin, while trading at a 13.2x P/E, indicates a high-quality compounder. This persistent cash generation from its essential creative and marketing tools ensures continuous reinvestment into its platform, sustaining its market leadership.
Moat. Adobe's moat is built on deep entrenchment within its Digital Media segment, where its products are industry standards for photographers, video editors, and graphic designers, creating high switching costs for professionals. The integrated platform in its Digital Experience segment further locks in brands and businesses by offering comprehensive solutions from analytics to commerce. This ecosystem dominance drives an exceptional 62.8% Return on Equity, reflecting strong pricing power and the mission-critical nature of its software.
Risk. The primary bear case for Adobe centers on potential deceleration in its core Digital Media segment due to increasing competition from lower-cost or open-source alternatives, threatening its pricing power. Despite a seemingly low P/E of 13.2x, the stock's high 1.43 beta suggests it remains susceptible to broader market downturns, especially if its 11.5% revenue growth rate continues to slow. A sustained period of declining subscriber growth within its creative cloud offerings would confirm the bear thesis, indicating a loss of its entrenched market position.
Horizon. 1-3 yr $272.48 (analyst consensus (n=33)) — fundamentals + valuation re-rating. 5 yr $398.93 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $591.79 if current growth sustains into durable earnings power.
3. INTU — Intuit Inc. · score 89.1
Software - Application · price $289.76 · 1Y $484.73 · 5Y $709.70 · 10Y $1,053
FCF $7.8b B+ · Rev +15.1% B+ · D/E 0.33 B · P/E 17.7x A- · PEG 0.71 A-
Why now. Intuit’s moat is the sticky QuickBooks‑Online ecosystem that now bundles payroll, payments and financing, driving relentless recurring revenue growth. The business is expanding at a 15.1% YoY revenue growth rate while generating $7.8B of free cash flow and delivering a stellar ROE of 22.2%, giving it a sub‑1.0 PEG of 0.71. The thesis rests on the compounding power of cross‑selling QuickBooks and Mailchimp to the same small‑business customer base, which should keep the growth engine humming for years.
Moat. QuickBooks embeds core accounting, payroll and payment processing into a single platform, creating high switching costs for SMBs that would need to re‑architect their finance stack elsewhere. This lock‑in fuels pricing power, reflected in a 22.2% ROE, and the addition of Mailchimp deepens the data moat by linking marketing spend to financial outcomes—an integration rivals can’t replicate quickly.
Risk. The biggest headwind is a potential slowdown in SMB spending that would blunt the 15.1% revenue growth rate, exposing the stock to a valuation correction despite its modest 17.7× P/E. Competitive pressure from other cloud‑accounting suites could erode market share, and a dip below the 52‑week low of $252.84 would signal that the growth premium is evaporating. A sustained drop in revenue growth or a breach of the low price level would invalidate the compounding thesis.
Horizon. 1-3 yr $484.73 (analyst consensus (n=32)) — fundamentals + valuation re-rating. 5 yr $709.70 at ~20% CAGR — compounding case rests on the competitive position widening. 10 yr $1,053 if current growth sustains into durable earnings power.
4. DLO — DLocal Limited · score 88.9
Software - Infrastructure · price $14.92 · 1Y $17.85 · 5Y $26.13 · 10Y $38.77
FCF $413m C · Rev +46.6% A · D/E 0.20 B+ · P/E 23.3x B+ · PEG 0.50 A
Why now. DLocal’s pay‑in platform for cross‑border merchants is exploding, driven by a 46.6% YoY revenue growth and a razor‑thin PEG of 0.5, indicating deep undervaluation of its growth trajectory. Coupled with a stellar ROE of 34.6%, the business can keep compounding cash while expanding into new e‑commerce and streaming partners, making the upside hinge on sustaining this high‑margin growth engine.
Moat. The moat lives in DLocal’s integrated pay‑in and pay‑out suite that locks global merchants into a single gateway for cards, bank transfers and hundreds of alternative payment methods, creating switching costs and network effects. Its 34.6% ROE stems from pricing power earned by being the de‑facto bridge for emerging‑market transactions, a capability hard for rivals to replicate quickly.
Risk. The bull thesis is vulnerable to a slowdown in cross‑border e‑commerce spending, which would blunt the 46.6% growth rate and pressure the current P/E of 23.3, a premium for a company still scaling. A sustained dip in margin or a rise in competition could push the stock back toward its 52‑week low of $9.81, confirming the bear case.
Horizon. 1-3 yr $17.85 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $26.13 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $38.77 if current growth sustains into durable earnings power.
5. NBIX — Neurocrine Biosciences, Inc. · score 87.1
Drug Manufacturers - Specialty & Generic · price $174.10 · 1Y $197.95 · 5Y $289.82 · 10Y $429.93
FCF $831m C+ · Rev +28.6% A- · D/E 0.14 B+ · P/E 26.8x B · PEG 0.50 A
Why now. Neurocrine Biosciences presents a compelling growth story, driven by the expanding market penetration of its commercial products like INGREZZA for tardive dyskinesia and a robust pipeline in neurological and psychiatric disorders. With revenue growth at a robust 28.6% (FY YoY) and an exceptional PEG ratio of 0.5, the company is compounding earnings efficiently, further supported by a strong 21.6% profit margin. The crux of the thesis rests on NBIX's ability to continue translating its development success in specialized neurological treatments into sustained market share gains and pipeline advancements.
Moat. Neurocrine's durable edge stems from its specialized focus on discovering and commercializing pharmaceuticals for complex neurological and psychiatric disorders, evidenced by successful products like INGREZZA. The significant intellectual property protection and the high regulatory barriers inherent in developing and gaining approval for novel treatments in these therapeutic areas create substantial switching costs for patients and prescribers, effectively insulating its market share. This specialized expertise and regulatory navigation contribute to its strong 19.6% ROE, reflecting pricing power and a protected market position.
Risk. The bear case centers on the inherent execution risk in pharmaceutical development, particularly given the company's reliance on a pipeline of candidates like NBI-1076986 and Osavampator for future growth in neurological and psychiatric disorders. While current revenue growth is strong, the market's current valuation, reflected in a P/E (TTM) of 26.8, leaves little room for error if a key clinical trial fails or if a competitor introduces a superior therapy. A sustained deceleration in revenue growth below its current 28.6% (FY YoY) would confirm the bear case, indicating a weakening of its product portfolio or pipeline prospects.
Horizon. 1-3 yr $197.95 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $289.82 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $429.93 if current growth sustains into durable earnings power.
6. LRN — Stride, Inc. · score 86.7
Education & Training Services · price $92.02 · 1Y $105.82 · 5Y $154.94 · 10Y $229.84
FCF $414m C · Rev +10.9% B · D/E 0.33 A- · P/E 14.4x A- · PEG 0.51 A-
Why now. Stride’s end‑to‑end virtual‑school platform is locking in a growing share of the $XX billion blended‑learning market, and that stickiness fuels compounding earnings. The business is delivering 10.9% revenue growth while maintaining a healthy 12.2% profit margin and generating $414 m of free cash flow on a $3.9 b market cap, giving a free‑cash‑flow yield of over 10%. With a PEG of 0.51 and a ultra‑low beta of 0.1, the upside rests on the platform’s ability to keep scaling its school‑district contracts and expand supplemental courses.
Moat. The integrated suite of curriculum, enrollment, tracking and support tools creates high switching costs for districts that have built entire virtual‑school operations on Stride’s technology, locking in recurring revenue. This stickiness translates into an ROE of 18.8%, driven by pricing power in a niche where few competitors can match the breadth of Stride’s bundled offering without a costly rebuild.
Risk. The stock is still trading far below its 52‑week high of $171.17, and any slowdown in the already modest 10.9% YoY revenue growth would force a re‑rating of the cheap PEG of 0.51. A dip in district enrollment or a shift to lower‑cost alternatives could compress the 12.2% margin, and a rise in debt‑to‑equity above the current 0.33 would add financial strain. A sustained decline in growth or margin would push the price back toward the lower end of the analyst range, confirming the bear case.
Horizon. 1-3 yr $105.82 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $154.94 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $229.84 if current growth sustains into durable earnings power.
7. NVDA — NVIDIA Corporation · score 85.7
Semiconductors · price $203.53 · 1Y $301.62 · 5Y $441.60 · 10Y $655.09
FCF $119.1b A · Rev +70.7% A · D/E 0.07 A- · P/E 31.1x B · PEG 0.65 A-
Why now. NVIDIA’s Compute & Networking segment is locked into the exploding AI infrastructure market, and its data‑center GPUs are the de‑facto engine for every enterprise generative‑AI deployment. That engine is expanding at +70.7% YoY revenue growth, backed by an industry‑leading 81.7% ROE and a still‑reasonable PE of 31.1, giving the business a compounding engine that will outpace peers for years. The thesis hinges on the relentless demand for AI‑accelerated compute that NVIDIA uniquely supplies.
Moat. NVIDIA’s moat lives in its proprietary GPU architecture and the software stack that ties customers to its ecosystem, creating massive switching costs for data‑center operators. The Compute & Networking segment’s pricing power—evidenced by an 81.7% ROE—stems from being the only provider that can deliver the performance per watt required for large‑scale AI workloads, a capability rivals cannot replicate quickly.
Risk. The stock trades at a lofty PE of 31.1 and a beta of 2.21, meaning any slowdown in AI spend or a broader market pullback could crush valuation multiples. A contraction in margin or a missed revenue growth target would validate the bear view, and a break below the 52‑week low of $162.02 would be the concrete signal that the growth engine is faltering.
Horizon. 1-3 yr $301.62 (analyst consensus (n=58)) — fundamentals + valuation re-rating. 5 yr $441.60 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $655.09 if current growth sustains into durable earnings power.
8. EXLS — ExlService Holdings, Inc. · score 85.6
Information Technology Services · price $28.49 · 1Y $41.00 · 5Y $60.03 · 10Y $89.05
FCF $297m C · Rev +13.4% B+ · D/E 0.67 C+ · P/E 18.1x A- · PEG 0.87 B+
Why now. EXLS is poised to ride the AI‑powered digital transformation of insurance and healthcare operations, where its analytics‑driven claims management and policy servicing platforms lock in long‑term contracts. The business is growing revenue at 13.4% YoY, converting that into a rock‑solid 32.3% ROE while trading at a sub‑1.0 PEG of 0.87, proving the market is undervaluing its compounding engine. The thesis rests on the relentless adoption of AI across regulated verticals that fuels recurring cash flow and margin expansion.
Moat. EXLS’s moat derives from its entrenched AI and data platform embedded in insurance claims and healthcare administration, creating high switching costs for carriers and providers. This embeddedness translates into pricing power that drives its 32.3% ROE, as clients pay premium fees for bespoke analytics that competitors cannot replicate quickly without comparable data depth.
Risk. The bear case hinges on a slowdown in insurance and healthcare spending that would blunt the 13.4% revenue growth, while the stock’s P/E of 18.1 suggests investors have already priced in near‑term expansion; any miss on growth would force a re‑rating. A rising debt‑to‑equity ratio toward 0.8 would also strain balance‑sheet flexibility. The bear signal is a sustained revenue growth dip below 8% coupled with margin compression, which would trigger a sell‑off toward the 52‑week low.
Horizon. 1-3 yr $41.00 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $60.03 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $89.05 if current growth sustains into durable earnings power.
9. HRMY — Harmony Biosciences Holdings, Inc. · score 85.2
Biotechnology · price $35.54 · 1Y $44.91 · 5Y $65.75 · 10Y $97.54
FCF $342m C · Rev +20.7% A- · D/E 0.18 B+ · P/E 14.3x A- · PEG 0.67 A-
Why now. Harmony Biosciences is a compelling growth story, demonstrating robust financial performance driven by the commercial success of WAKIX for narcolepsy and the expanding pipeline for Pitolisant into new rare neurological diseases like Prader-Willi Syndrome. With revenue growing at 20.7% and a remarkably low 0.67 PEG ratio, the company is generating substantial free cash flow of $342m, indicating significant undervaluation for a profitable biotech. The core thesis rests on the continued market penetration of WAKIX and successful clinical advancements of Pitolisant in its various Phase 2 and 3 trials.
Moat. Harmony Biosciences' competitive edge is anchored by WAKIX (pitolisant), a therapy with a novel mechanism of action specifically for excessive daytime sleepiness in narcolepsy, providing a differentiated offering in a specialized market. This unique pharmacological profile, combined with its ongoing development for additional rare neurological diseases such as Prader-Willi Syndrome and Myotonic Dystrophy, establishes a strong intellectual property moat that is difficult for competitors to replicate quickly. The company's focus on rare neurological diseases allows for targeted commercialization and deep expertise, reinforcing its market position.
Risk. The primary bear case for Harmony Biosciences centers on its heavy reliance on the single molecule, Pitolisant, which underpins both its commercial product WAKIX and its entire pipeline for other rare neurological diseases. Any clinical trial failure for Pitolisant in Phase 3 for Prader-Willi Syndrome or Phase 2 for Myotonic Dystrophy would severely curtail future growth prospects, especially given the wide analyst target range of $28–$85 which highlights significant uncertainty. A concrete signal confirming the bear case would be a negative data readout from a pivotal Pitolisant trial or a sustained deceleration in WAKIX's revenue growth.
Horizon. 1-3 yr $44.91 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $65.75 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $97.54 if current growth sustains into durable earnings power.
10. ADMA — ADMA Biologics, Inc. · score 84.1
Biotechnology · price $8.97 · 1Y $17.60 · 5Y $25.77 · 10Y $38.23
FCF $108m C · Rev +11.0% B · D/E 1.11 C · P/E 13.2x A- · PEG 0.67 A-
Why now. ADMA’s moat lies in its niche IVIG franchise—BIVIGAM and ASCENIV dominate the U.S. primary humoral immunodeficiency market, delivering a 32.4% profit margin, a 42.4% ROE, and a 13.2× P/E that still reflects growth, not hype. The business compounds on a solid 11% YoY revenue growth while free cash flow of $108 M funds expansion of its plasma collection network, making the upside hinge on continued market share capture in immune‑deficiency therapies.
Moat. ADMA controls a vertically integrated plasma supply chain through its ADMA BioManufacturing and Plasma Collection Centers, creating high switching costs for hospitals that rely on its proprietary IVIG products. This integration yields pricing power in a fragmented market, underpinning the 42.4% ROE and sustaining margins above 30% that competitors struggle to match without similar collection capacity.
Risk. The bear case centers on the concentration in the IVIG segment; any adverse regulatory finding or successful biosimilar entry could compress the 13.2× P/E and erode the 32.4% margin. A rising debt‑to‑equity of 1.11 adds leverage risk if cash flow falters. The thesis collapses if the 52‑week low of $7.21 becomes a new floor, signaling market skepticism about growth sustainability.
Horizon. 1-3 yr $17.60 (analyst consensus (n=5)) — fundamentals + valuation re-rating. 5 yr $25.77 at ~23% CAGR — compounding case rests on the competitive position widening. 10 yr $38.23 if current growth sustains into durable earnings power.
11. CARG — CarGurus, Inc. · score 83.7
Auto & Truck Dealerships · price $33.75 · 1Y $37.38 · 5Y $54.73 · 10Y $81.20
FCF $293m C · Rev +14.0% B+ · D/E 0.79 B · P/E 17.8x B+ · PEG 1.04 B+
Why now. CarGurus is a high-quality compounder, leveraging its dominant online automotive platform to connect a large audience of car shoppers with an extensive network of dealers. The company's impressive 14% FY YoY revenue growth, combined with a robust 15.9% profit margin and a highly efficient 1.04 PEG ratio, demonstrates its ability to grow profitably. The ongoing expansion of its integrated suite of products, including "Digital Deal," ensures persistent compounding by deepening engagement and revenue per dealer and shopper.
Moat. The company's 62.9% ROE is a clear indicator of its powerful network effect, where a large audience of car shoppers attracts an extensive network of dealers, and vice-versa, creating significant switching costs. This dynamic is reinforced by CarGurus' integrated suite of products, including "Digital Deal" and "Dealership Mode," which embed the platform deeply into both the consumer and dealer purchase process. This structural advantage ensures sustained pricing power and makes it challenging for competitors to replicate the scale and value proposition.
Risk. The primary bear case centers on the inherent cyclicality of the "Auto & Truck Dealerships" sector, which could pressure CarGurus' growth trajectory if vehicle sales slow significantly. While current growth is strong, the company's relatively high 1.18 beta suggests it is more sensitive to market downturns, and a 0.79 debt-to-equity ratio, while manageable, could become a concern if revenue growth decelerates. A sustained contraction in the number of active dealers or a significant drop in advertising from auto manufacturers would confirm a weakening competitive position and validate the bear thesis.
Horizon. 1-3 yr $37.38 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $54.73 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $81.20 if current growth sustains into durable earnings power.
12. EPAM — EPAM Systems, Inc. · score 83.3
Information Technology Services · price $86.38 · 1Y $139.06 · 5Y $203.60 · 10Y $302.02
FCF $544m C+ · Rev +14.2% B+ · D/E 0.08 B+ · P/E 12.4x A · PEG 0.43 A
Why now. EPAM’s digital platform engineering franchise is exploding, driven by its cloud‑enabled migration services that lock in multi‑year contracts and high‑margin consulting fees. The business is growing revenue at 14.2% YoY while delivering a free‑cash‑flow runway of $544 m on a $4.5 b market cap, yielding an attractive 12% FCF yield. Coupled with a rock‑bottom PEG of 0.43, the compounding engine of platform‑centric digital transformation will keep earnings expanding for the next decade.
Moat. EPAM’s moat lives in its end‑to‑end engineering platform that spans requirements analysis, cloud roadmap, AI/analytics, and smart automation, creating deep integration with enterprise IT stacks. Large‑scale customers face costly re‑platforming and data‑migration hurdles, locking them into EPAM’s services and generating sticky, high‑margin revenue. This operational lock‑in fuels the 11.3% ROE, far above the industry average, and cannot be replicated quickly by pure‑play developers.
Risk. The biggest headwind is the premium valuation implied by a P/E of 12.4 in a sector where peers trade at sub‑10 multiples, suggesting the market has already priced in the growth premium. Any slowdown in digital‑transformation spend or a shift to lower‑cost offshore vendors would compress margins, and a rise in debt (currently low at 0.08 but could creep up) would erode the balance‑sheet advantage. A sustained dip below the 52‑week low of $73.06 would trigger stop‑loss selling and invalidate the growth narrative.
Horizon. 1-3 yr $139.06 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $203.60 at ~19% CAGR — compounding case rests on the competitive position widening. 10 yr $302.02 if current growth sustains into durable earnings power.
13. RMD — ResMed Inc. · score 82.8
Medical Instruments & Supplies · price $198.50 · 1Y $256.07 · 5Y $374.91 · 10Y $556.15
FCF $1.8b C+ · Rev +10.3% B · D/E 0.13 B+ · P/E 19.1x A- · PEG 1.20 B+
Why now. ResMed’s dominance in cloud‑connected sleep diagnostics, epitomized by its ApneaLink Air and NightOwl platforms, fuels a relentless compounding engine as clinicians shift to remote monitoring. The business is growing revenue at 10.3% YoY, converting that into a robust 27.4% profit margin and a stellar 23.4% ROE, proving the model scales profitably. The thesis rests on the expanding home‑sleep market and the stickiness of its data‑rich software suite, which will keep earnings accelerating.
Moat. The ApneaLink Air and NightOwl devices embed proprietary algorithms and cloud analytics that lock hospitals, sleep clinics, and home users into a single data ecosystem, creating high switching costs. This platform lock‑in underpins ResMed’s pricing power, reflected in a >20% ROE, and cannot be replicated quickly because it requires both hardware certification and a mature software backend.
Risk. A bear argues that the premium valuation—P/E of 19.1 versus modest 10% revenue growth—leaves little margin for error, and any slowdown in the shift to home‑based sleep care would compress margins. The debt‑to‑equity of 0.13 is low, but a rise in interest rates could pressure the balance sheet, and a miss on the consensus 1‑yr target of $256.07 would signal the growth story is fading. A sustained drop below the 52‑week low of $180.27 would confirm the downside.
Horizon. 1-3 yr $256.07 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $374.91 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $556.15 if current growth sustains into durable earnings power.
14. IT — Gartner, Inc. · score 82.7
Information Technology Services · price $141.31 · 1Y $164.23 · 5Y $240.45 · 10Y $356.69
FCF $1.3b C+ · Rev +2.3% C · D/E n/a · P/E 13.9x A- · PEG 0.54 A-
Why now. Gartner's valuation is compelling for a high-quality compounder, trading at a mere 13.9x TTM P/E and an exceptionally low 0.54 PEG ratio, signaling significant undervaluation relative to its earnings growth prospects. The company generates robust cash flow, evidenced by $1.3b in TTM Free Cash Flow against a $9.5b market cap, underscoring its ability to fund future growth and shareholder returns. The crux lies in the persistent demand for its mission-critical "Insights" subscription services, which provides a stable, high-margin revenue base poised for compounding.
Moat. Gartner's durable edge stems from its deeply embedded "Insights" subscription services, which provide mission-critical "data and benchmarks" and "direct access to a network of business and technology experts." This creates high switching costs for organizations that rely on Gartner's specialized intelligence for strategic decision-making. The company also benefits from a network effect within its "Conferences" segment, where executives learn and network through its Symposium/Xpo series, further solidifying its position as an indispensable resource.
Risk. The bear case hinges on Gartner's anemic 2.3% FY YoY revenue growth, which is a significant red flag for a company positioned as a "growth" compounder and suggests potential saturation or intensified competition in its "business and technology insights" market. This deceleration is reflected in the stock's dramatic fall from its 52-week high of $375.84 to its current $141.31, indicating a loss of investor confidence in its growth narrative. A sustained period of single-digit revenue growth, particularly within its core "Insights" subscription services, would confirm the bear thesis that its market leadership is eroding.
Horizon. 1-3 yr $164.23 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $240.45 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $356.69 if current growth sustains into durable earnings power.
15. VEEV — Veeva Systems Inc. · score 82.1
Health Information Services · price $196.81 · 1Y $244.59 · 5Y $358.11 · 10Y $531.23
FCF $1.7b C+ · Rev +16.2% B+ · D/E 0.01 A- · P/E 34.8x C+ · PEG 0.86 B+
Why now. Veeva’s Vault CRM Suite is cementing its position as the de‑facto operating system for pharma and biotech commercial teams, and that lock‑in is fueling a 16.2% YoY revenue growth while preserving a 28.4% profit margin. The PEG of 0.86 shows the market is pricing growth too cheaply relative to earnings, giving the stock a clear upside as recurring SaaS contracts compound. The thesis rests on the relentless expansion of Veeva’s cloud platform across life‑science customers, which guarantees multi‑year cash‑flow growth.
Moat. Veeva’s integrated Vault suite (CRM, PromoMats, Medical, Crossix) creates a high‑switching‑cost ecosystem for regulated life‑science firms; once a drug company embeds Vault into its compliance, data, and commercial workflows, migration is prohibitively complex. This sticky, industry‑specific platform, combined with near‑zero debt (D/E 0.01) and a disciplined cost structure, locks in pricing power and protects margins.
Risk. The stock trades at a lofty PE of 34.8 despite a 16% growth rate, implying investors are already betting on continued acceleration; any slowdown in pharma digital spend or a successful inroad by generic cloud rivals would compress the multiple and pressure the share price. A breach of the 30% PE ceiling would be a clear bear signal.
Horizon. 1-3 yr $244.59 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $358.11 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $531.23 if current growth sustains into durable earnings power.
16. DXCM — DexCom, Inc. · score 80.7
Medical Devices · price $76.35 · 1Y $85.24 · 5Y $124.80 · 10Y $185.13
FCF $1.4b C+ · Rev +16.1% B+ · D/E 0.47 B · P/E 32.8x C+ · PEG 1.40 B
Why now. DexCom’s G7 platform is cementing its dominance in the CGM market, and the 16.1% YoY revenue growth proves the rollout is gaining traction. Coupled with a 19.3% profit margin and a stellar 31.5% ROE, the business is compounding earnings faster than most growth peers. The thesis rests on continued G7 adoption across the U.S. and international diabetes care ecosystems.
Moat. The G7 and G7 15‑Day sensors lock in endocrinologists and patients through Dexcom Share and Follow apps, creating a data‑rich ecosystem that is costly to replace. DexCom’s FDA‑cleared algorithms and proprietary sensor chemistry give it a patent‑protected edge, while the high switching cost of re‑training clinicians and patients sustains pricing power and market share.
Risk. A 32.8× forward P/E and a beta of 1.45 signal that the stock is priced for near‑term perfection; any slowdown in G7 uptake or a successful launch by a rival CGM could compress margins and force the valuation down. A breach of the 52‑week low ($54.11) would confirm the market’s doubt and trigger a sell‑off.
Horizon. 1-3 yr $85.24 (analyst consensus (n=25)) — fundamentals + valuation re-rating. 5 yr $124.80 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $185.13 if current growth sustains into durable earnings power.
17. CVSA — Covista Inc. · score 80.1
Education & Training Services · price $133.18 · 1Y $156.25 · 5Y $228.77 · 10Y $339.36
FCF $336m C · Rev +9.7% B · D/E 0.54 B+ · P/E 19.4x B · PEG 0.88 B+
Why now. Covista’s growth engine is its Chamberlain and Walden online health‑professionals platforms, which are scaling enrollment faster than the broader education market. The business is delivering 9.7% revenue growth YoY while maintaining a healthy 12.3% profit margin and trading at a sub‑1.0 PEG of 0.88, proving earnings are compounding on a solid cash‑flow base. The thesis rests on the relentless demand for accredited nursing and health‑policy degrees that lock students into multi‑year tuition streams, ensuring the compounding momentum will persist.
Moat. Covista’s moat lies in its accredited, credit‑bearing degree pipelines—Chamberlain University, Walden University, and the Caribbean medical school—where switching costs are high because students must transfer credits and meet strict licensure standards. This regulatory lock‑in fuels pricing power, reflected in a 17.2% ROE, and cannot be duplicated quickly by new entrants without costly accreditation and faculty investments.
Risk. The bear case focuses on the premium valuation and modest growth: a forward P/E of 19.4 is elevated for a single‑digit growth rate, and revenue expansion has slowed to 9.7% YoY, leaving little headroom for margin expansion. Debt‑to‑equity at 0.54 adds leverage risk if enrollment dips. A breach of the analyst consensus target—price slipping below the 52‑week low of $86.97—would signal that growth expectations are overstated and could trigger a sell‑off.
Horizon. 1-3 yr $156.25 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $228.77 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $339.36 if current growth sustains into durable earnings power.
18. PODD — Insulet Corporation · score 79.3
Medical Devices · price $162.06 · 1Y $238.67 · 5Y $349.43 · 10Y $518.36
FCF $416m C · Rev +31.9% A · D/E 0.78 C+ · P/E 38.0x C+ · PEG 1.42 B
Why now. Insulet Corporation is a high-quality compounder, poised for continued market penetration with its innovative Omnipod 5 automated insulin delivery system. The company's impressive 31.9% FY YoY revenue growth, coupled with a strong 23.2% ROE and $416m in free cash flow, demonstrates robust operational efficiency and capital generation. The thesis rests on the persistent adoption of its integrated Omnipod platform, which simplifies insulin management for a growing base of insulin-dependent individuals.
Moat. Insulet's durable edge stems from its proprietary Omnipod platform, specifically the Omnipod 5's embedded AID algorithm and its seamless integration with third-party continuous glucose monitors. This creates significant switching costs for users who become accustomed to the convenience and efficacy of the system, driving the exceptional 23.2% ROE through recurring consumable sales and pricing power from category leadership in tubeless insulin delivery. Competitors face a high barrier to entry in replicating this integrated, user-friendly ecosystem.
Risk. The primary bear case against Insulet centers on its elevated valuation and the competitive landscape within medical devices for diabetes management. Trading at a P/E TTM of 38, the stock is priced for perfection, and any slowdown in the adoption of its Omnipod platform or increased competition could lead to a significant re-rating, especially given its current price of $162.06 is far below its 52-week high of $354.88. A sustained deceleration in revenue growth below the current 31.9% due to new market entrants or pricing pressure would confirm the bear thesis.
Horizon. 1-3 yr $238.67 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $349.43 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $518.36 if current growth sustains into durable earnings power.
19. MELI — MercadoLibre, Inc. · score 79.1
Internet Retail · price $1867.30 · 1Y $2,209 · 5Y $3,234 · 10Y $4,797
FCF $11.8b A- · Rev +36.4% A · D/E 1.70 C+ · P/E 49.2x C · PEG 1.14 B+
Why now. MELI will keep compounding because its Mercado Pago ecosystem locks merchants and shoppers into a cash‑flow loop that fuels cross‑selling, and that loop is expanding at a blistering 36.4% revenue growth rate while delivering a rock‑solid 26.4% ROE and generating $11.8B of free cash flow – the cash engine that funds the next wave of logistics and credit rollout. The thesis rests on the relentless network‑effect of Mercado Pago driving higher margins and higher spend per user.
Moat. The moat lives in the integrated Marketplace‑to‑Payments‑to‑Credit stack: sellers on Mercado Libre must use Mercado Pago to accept payments, which then feeds into Mercado Credito and Mercado Fondo, creating high switching costs and a data moat that lets MELI price credit competitively and keep merchants locked in. This end‑to‑end funnel fuels the 26.4% ROE, a return only achievable with such a tightly coupled ecosystem.
Risk. The stock trades at a lofty PE of 49.2 and a debt‑to‑equity of 1.7, meaning any slowdown in the 36.4% revenue growth or a margin squeeze would force a painful valuation correction; a sustained dip below the 52‑week low of $1,495 would confirm the bear case that the growth premium is unsustainable.
Horizon. 1-3 yr $2,209 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $3,234 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $4,797 if current growth sustains into durable earnings power.
20. FIVE — Five Below, Inc. · score 78.5
Specialty Retail · price $191.53 · 1Y $260.33 · 5Y $381.15 · 10Y $565.42
FCF $505m C+ · Rev +25.9% A- · D/E 0.86 B · P/E 24.1x B · PEG 0.98 B+
Why now. Five Below’s rapid expansion of its personalized living‑space assortment – lamps, posters, plush décor and accent furniture – is fueling a revenue surge of +25.9% YoY, creating a compounding growth engine. The business backs this with a healthy free‑cash‑flow conversion of $505 m and a sub‑1.0 PEG of 0.98, proving earnings can keep pace with top‑line expansion. The thesis hinges on sustaining this niche‑decor momentum, which will keep the growth curve steep for years to come.
Moat. Five Below locks in teen‑and‑young‑adult shoppers with a constantly refreshed, low‑price novelty décor and gift mix that larger chains can’t replicate quickly due to higher inventory turn costs. Its 19% ROE stems from pricing power in these high‑margin, trend‑driven categories, creating a sticky foot‑traffic loop that drives repeat visits and protects margins.
Risk. The biggest headwind is the encroachment of big‑box discounters and online marketplaces that can undercut Five Below’s price advantage, threatening its 8.7% profit margin. A P/E of 24.1 is already premium for a specialty retailer, and any slowdown in the 25.9% revenue growth rate would compress that multiple further. A rise in debt‑to‑equity above 0.86 or a margin dip below 8% would signal the bear case materializing.
Horizon. 1-3 yr $260.33 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $381.15 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $565.42 if current growth sustains into durable earnings power.
21. APP — AppLovin Corporation · score 78.4
Advertising Agencies · price $442.85 · 1Y $654.60 · 5Y $958.40 · 10Y $1,422
FCF $4.4b B · Rev +66.4% A · D/E 1.63 C · P/E 38.5x C+ · PEG 1.39 B
Why now. AppLovin’s compounding engine is its MAX in‑app bidding platform, which locks publishers into a real‑time auction that extracts ever‑higher yields as inventory scales. That engine is fueling a 66.4% FY YoY revenue surge, a 64.3% profit margin, and $4.4B of free cash flow – a rare trio for a growth megacap. As long as MAX continues to dominate mobile inventory auctions, the revenue multiple can stay elevated and the upside stays locked to the 66% growth runway.
Moat. MAX creates a two‑sided network effect: publishers receive higher eCPMs while advertisers gain instant access to premium inventory, making switching costly. Coupled with Adjust’s analytics lock‑in, AppLovin owns the data pipeline that competitors can’t replicate quickly, preserving pricing power and high margins.
Risk. The stock trades at a lofty 38.5× PE and a beta of 2.48, meaning any slowdown in the 66% growth rate or a market pull‑back will hammer valuation. A dip in YoY revenue growth below 30% would validate the bear view and trigger a sharp re‑rating.
Horizon. 1-3 yr $654.60 (analyst consensus (n=30)) — fundamentals + valuation re-rating. 5 yr $958.40 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $1,422 if current growth sustains into durable earnings power.
22. META — Meta Platforms, Inc. · score 78.3
Internet Content & Information · price $656.73 · 1Y $828.34 · 5Y $1,213 · 10Y $1,799
FCF $48.3b A · Rev +26.2% A- · D/E 0.36 B+ · P/E 23.9x B · PEG 0.97 B+
Why now. Meta’s Family of Apps is on a compounding revenue runway, delivering 26.2% YoY growth while preserving a 32.8% profit margin and a stellar 29% ROE. The network effects of Facebook, Instagram and Messenger keep user engagement high, feeding ad demand that scales faster than the market, and the 8% upside to the consensus 1‑yr target underscores the near‑term upside. The thesis hinges on the FoA segment’s ability to keep monetizing its massive global user base at expanding margins.
Moat. Meta’s moat lives in the entrenched social graph across its Family of Apps, where billions of daily interactions create a data moat that fuels superior ad targeting and pricing power, driving the 29% ROE. Switching costs are high because users and advertisers are locked into a single, integrated ecosystem of feed, reels, stories and marketplace, which competitors cannot replicate quickly without comparable scale.
Risk. The bear case centers on the elevated valuation—PE of 23.9x on a megacap stock—combined with a beta of 1.25 that amplifies market volatility, and a debt‑to‑equity of 0.36 that could rise if Reality Labs drags on. A slowdown in ad spend or a misstep in the Reality Labs rollout would compress margins and force the stock back toward its 52‑week low of $520.26, confirming the downside.
Horizon. 1-3 yr $828.34 (analyst consensus (n=58)) — fundamentals + valuation re-rating. 5 yr $1,213 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $1,799 if current growth sustains into durable earnings power.
23. DECK — Deckers Outdoor Corporation · score 78.2
Footwear & Accessories · price $107.80 · 1Y $126.86 · 5Y $185.73 · 10Y $275.52
FCF $1.1b C+ · Rev +9.8% B · D/E 0.15 A · P/E 15.4x B+ · PEG 1.32 B
Why now. The bull case hinges on the unstoppable expansion of the HOKA performance‑footwear franchise, which is driving top‑line momentum and cash generation. Revenue is climbing at 9.8% YoY, profit margins sit at a healthy 18.7%, and free cash flow hits $1.1 B on a $15 B market cap, delivering a compelling cash‑flow yield that fuels reinvestment and shareholder returns. The thesis rests on the ability to keep compounding this cash‑rich growth as HOKA and UGG dominate their premium niches.
Moat. Deckers’ moat derives from category leadership in premium performance (HOKA) and casual luxury (UGG), which commands pricing power and yields a ROE of 41%—far above industry averages. The combined brand‑specific design expertise and a tightly controlled distribution network across high‑margin retail partners create switching costs that rivals cannot quickly replicate.
Risk. The bear case focuses on a potential slowdown in discretionary spending that would blunt the 9.8% revenue growth and compress the 18.7% profit margin, while the stock trades at a forward P/E of 15.4 with a PEG of 1.32, suggesting limited upside if growth stalls. A widening gap between analyst target range and the 52‑week low would signal market skepticism; a sustained drop below $90 would confirm the downside.
Horizon. 1-3 yr $126.86 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $185.73 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $275.52 if current growth sustains into durable earnings power.
24. NFLX — Netflix, Inc. · score 78.1
Entertainment · price $73.83 · 1Y $113.15 · 5Y $165.66 · 10Y $245.74
FCF $11.9b A- · Rev +16.7% B+ · D/E 0.54 B · P/E 23.8x B · PEG 1.44 B
Why now. Netflix's global entertainment services are a compounding machine, evidenced by its robust 16.7% FY YoY revenue growth and impressive 28.5% profit margin. With $11.9b in TTM free cash flow, the company has ample resources to fuel its content engine and expand its streaming content offerings worldwide, ensuring sustained subscriber growth and pricing power.
Moat. Netflix's durable edge stems from its vast and diverse library of television series, documentaries, feature films, games, and live programming, which creates significant switching costs for its global subscriber base. This extensive content portfolio, accessible across a host of internet-connected devices, underpins its exceptional 43% Return on Equity, allowing it to command pricing power and attract new members globally.
Risk. Despite its market leadership, Netflix faces a persistent bear case centered on intense competition within the global entertainment sector, which could pressure its 28.5% profit margin. The stock's high 1.52 beta also signals vulnerability to broader market downturns, and a sustained deceleration in its 16.7% revenue growth, coupled with escalating content costs, would confirm the bear thesis.
Horizon. 1-3 yr $113.15 (analyst consensus (n=44)) — fundamentals + valuation re-rating. 5 yr $165.66 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $245.74 if current growth sustains into durable earnings power.
25. MU — Micron Technology, Inc. · score 76.8
Semiconductors · price $937.00 · 1Y $1,486 · 5Y $1,876 · 10Y $2,406
FCF $26.2b A · Rev +167.0% A · D/E 0.06 A- · P/E 21.2x B+ · PEG 0.14 A
Why now. Semiconductors · market cap $1.1T. Down 25% from 52-week high of $1255.00 — deep drawdown territory. Revenue growing +167% — in hypergrowth territory. PEG 0.14 — paying under fair value for the growth rate. 42 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $1,486 (implying +59% upside).
Moat. Net margin 56% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 50% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $1.1T market cap places it among the largest companies in the sector — distribution, R&D, and customer-acquisition costs amortize across a base peers can't replicate.
Risk. Beta 2.14 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. P/S 11.7x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard. Semiconductor cyclicality — inventory corrections compress margins faster than analysts model. Monitor channel inventory and book-to-bill ratios as leading indicators.
Horizon. 1-3 yr $1,486 (analyst consensus (n=42)) — multiple re-rating thesis requires a catalyst. 5 yr $1,876 at ~15% CAGR — dividend + buyback compounding. 10 yr $2,406 if the moat survives secular pressure.
26. YUMC — Yum China Holdings, Inc. · score 76.2
Restaurants · price $43.90 · 1Y $61.34 · 5Y $89.81 · 10Y $133.23
FCF $931m C+ · Rev +6.7% C+ · D/E 0.38 A- · P/E 16.8x B+ · PEG 1.08 B+
Why now. Restaurants · market cap $15.1b. Down 25% from 52-week high of $58.39 — deep drawdown territory. 21 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $61.34 (implying +40% upside).
Moat. ROE 17% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 98% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Horizon. 1-3 yr $61.34 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $89.81 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $133.23 if current growth sustains into durable earnings power.
27. FISV — Fiserv, Inc. · score 75.8
Sector n/a · price $51.18 · 1Y $67.56 · 5Y $85.29 · 10Y $109.38
FCF $4.1b B · Rev +9.3% B · D/E n/a · P/E 8.7x A- · PEG 2.41 C
Why now. Sector n/a · market cap $27.3b. Down 70% from 52-week high of $168.93 — deep drawdown territory. 27 sell-side analysts rate this a Hold with a mean 1-yr target of $67.56 (implying +32% upside).
Moat. Net margin 20% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 12% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 129% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 70% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $67.56 (analyst consensus (n=27)) — multiple re-rating thesis requires a catalyst. 5 yr $85.29 at ~11% CAGR — dividend + buyback compounding. 10 yr $109.38 if the moat survives secular pressure.
28. ULTA — Ulta Beauty, Inc. · score 75.2
Specialty Retail · price $473.33 · 1Y $623.58 · 5Y $912.99 · 10Y $1,354
FCF $1.1b C+ · Rev +11.3% B · D/E 0.89 B · P/E 17.7x B+ · PEG 1.63 C+
Why now. Specialty Retail · market cap $20.3b. Down 34% from 52-week high of $714.97 — deep drawdown territory. Revenue growing +11%, comfortably above the S&P median. 24 sell-side analysts rate this a Buy with a mean 1-yr target of $623.58 (implying +32% upside).
Moat. ROE 46% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 95% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 34% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $623.58 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $912.99 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $1,354 if current growth sustains into durable earnings power.
29. DEO — Diageo plc · score 74.5
Beverages - Wineries & Distilleries · price $82.50 · 1Y $101.14 · 5Y $148.08 · 10Y $219.67
FCF n/a · Rev +4.8% C+ · D/E 1.77 C · P/E 19.1x B · PEG 0.80 A-
Why now. Beverages - Wineries & Distilleries · market cap $45.9b. Down 29% from 52-week high of $116.41 — deep drawdown territory. PEG 0.80 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Buy with a mean 1-yr target of $101.14 (implying +23% upside).
Moat. Net margin 16% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 41% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk. Dividend payout 96% of earnings on a 4.0% yield — distribution coverage is thin; one earnings stumble could force a dividend cut.
Horizon. 1-3 yr $101.14 (analyst consensus (n=7)) — fundamentals + valuation re-rating. 5 yr $148.08 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $219.67 if current growth sustains into durable earnings power.
30. EME — EMCOR Group, Inc. · score 74.3
Engineering & Construction · price $764.90 · 1Y $1,000 · 5Y $1,263 · 10Y $1,619
FCF $1.1b C+ · Rev +18.3% B+ · D/E 0.13 A- · P/E 25.7x B+ · PEG 0.42 A
Why now. Engineering & Construction · market cap $34.1b. 20% off the 52-week high of $951.96. Revenue growing +18%, comfortably above the S&P median. PEG 0.42 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Buy with a mean 1-yr target of $1,000 (implying +31% upside).
Moat. ROE 35% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $1,000 (analyst consensus (n=7)) — multiple re-rating thesis requires a catalyst. 5 yr $1,263 at ~11% CAGR — dividend + buyback compounding. 10 yr $1,619 if the moat survives secular pressure.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.